Clinical Trials Browser

Phase 2 × Carcinoma, Ovarian Epithelial × Tyrosine Kinase Inhibitors × Clear all

NCT05422183 2022-06-16

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 2 Unknown

Carcinoma, Ovarian Epithelial